Rate of diagnoses and cost following thyroid imaging after benign fine-needle aspiration.
Follow-up imaging of the thyroid after benign fine-needle aspiration (FNA) is costly and results only in a small rate of subsequent malignancy detection, according to a study published in the American Journal of Roentgenology.
Researchers from Pennsylvania, Maryland, and Michigan sought to determine patterns, the cost of imaging tumor surveillance, and the rate of subsequent cancer detection in patients after an FNA biopsy of the thyroid.
The study included patients who had a benign thyroid FNA biopsy between January 1, 1999, and December 31, 2003, as identified from an institutional pathology database. Information was gathered from electronic medical records on imaging tumor surveillance and subsequent cancer detection. Cost was determined using the facility total relative value unit and the 2014 Hospital Outpatient Prospective Payment System conversion factor.
The results showed that 1,685 patients were determined to have a benign thyroid FNA biopsy, 800 (47.5%) of whom underwent follow-up imaging. The total cost for the procedures was $879,347 or $1099 per patient:
The mean length of follow-up was 7.3 years, during which time 19 (2.4%) patients were diagnosed with thyroid cancer at a cost of $46,281 per cancer. Seventeen (89.5%) were diagnosed with papillary carcinoma and two (10.5%) with Hurthle cell carcinoma.
The researchers concluded that although half of patients with a benign thyroid FNA biopsy underwent follow-up imaging, it was at considerable cost with a small rate of subsequent malignancy.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.